Search details
1.
Palbociclib with Fulvestrant or Letrozole in Endocrine-Sensitive Patients with HR-Positive/HER2-Negative Advanced Breast Cancer: A Detailed Safety Analysis of the Randomized PARSIFAL Trial.
Oncologist
; 28(1): 23-32, 2023 01 18.
Article
in English
| MEDLINE | ID: mdl-36239405
2.
The oral selective estrogen receptor degrader GDC-0810 (ARN-810) in postmenopausal women with hormone receptor-positive HER2-negative (HR + /HER2 -) advanced/metastatic breast cancer.
Breast Cancer Res Treat
; 197(2): 319-331, 2023 Jan.
Article
in English
| MEDLINE | ID: mdl-36401732
3.
Tailoring Adjuvant Endocrine Therapy for Premenopausal Breast Cancer.
N Engl J Med
; 379(2): 122-137, 2018 Jul 12.
Article
in English
| MEDLINE | ID: mdl-29863451
4.
Oral metronomic vinorelbine combined with endocrine therapy in hormone receptor-positive HER2-negative breast cancer: SOLTI-1501 VENTANA window of opportunity trial.
Breast Cancer Res
; 21(1): 108, 2019 09 18.
Article
in English
| MEDLINE | ID: mdl-31533777
5.
Adjuvant ovarian suppression in premenopausal breast cancer.
N Engl J Med
; 372(5): 436-46, 2015 Jan 29.
Article
in English
| MEDLINE | ID: mdl-25495490
6.
Changes in metabolic risk, insulin resistance, leptin and adiponectin following a lifestyle intervention in overweight and obese breast cancer survivors.
Eur J Cancer Care (Engl)
; 27(4): e12861, 2018 Jul.
Article
in English
| MEDLINE | ID: mdl-29869823
7.
Adjuvant ovarian function suppression and cognitive function in women with breast cancer.
Br J Cancer
; 114(9): 956-64, 2016 04 26.
Article
in English
| MEDLINE | ID: mdl-27092785
8.
Bosutinib in combination with the aromatase inhibitor exemestane: a phase II trial in postmenopausal women with previously treated locally advanced or metastatic hormone receptor-positive/HER2-negative breast cancer.
Oncologist
; 19(4): 346-7, 2014 Apr.
Article
in English
| MEDLINE | ID: mdl-24674873
9.
Bosutinib in combination with the aromatase inhibitor letrozole: a phase II trial in postmenopausal women evaluating first-line endocrine therapy in locally advanced or metastatic hormone receptor-positive/HER2-negative breast cancer.
Oncologist
; 19(4): 348-9, 2014 Apr.
Article
in English
| MEDLINE | ID: mdl-24674874
10.
Phase Ia/b Study of Giredestrant ± Palbociclib and ± Luteinizing Hormone-Releasing Hormone Agonists in Estrogen Receptor-Positive, HER2-Negative, Locally Advanced/Metastatic Breast Cancer.
Clin Cancer Res
; 30(4): 754-766, 2024 02 16.
Article
in English
| MEDLINE | ID: mdl-37921755
11.
SEOM-GEICAM-SOLTI clinical guidelines in advanced breast cancer (2022).
Clin Transl Oncol
; 25(9): 2665-2678, 2023 Sep.
Article
in English
| MEDLINE | ID: mdl-37148499
12.
Palbociclib Rechallenge for Hormone Receptor-Positive/HER-Negative Advanced Breast Cancer: Findings from the Phase II BioPER Trial.
Clin Cancer Res
; 29(1): 67-80, 2023 01 04.
Article
in English
| MEDLINE | ID: mdl-36165912
13.
Circulating tumor DNA reveals complex biological features with clinical relevance in metastatic breast cancer.
Nat Commun
; 14(1): 1157, 2023 03 01.
Article
in English
| MEDLINE | ID: mdl-36859416
14.
Adjuvant Endocrine Therapy in Premenopausal Breast Cancer: 12-Year Results From SOFT.
J Clin Oncol
; 41(7): 1370-1375, 2023 03 01.
Article
in English
| MEDLINE | ID: mdl-36493334
15.
Giredestrant reverses progesterone hypersensitivity driven by estrogen receptor mutations in breast cancer.
Sci Transl Med
; 14(663): eabo5959, 2022 Sep 21.
Article
in English
| MEDLINE | ID: mdl-36130016
16.
Preclinical In Vivo Validation of the RAD51 Test for Identification of Homologous Recombination-Deficient Tumors and Patient Stratification.
Cancer Res
; 82(8): 1646-1657, 2022 04 15.
Article
in English
| MEDLINE | ID: mdl-35425960
17.
High p16 expression and heterozygous RB1 loss are biomarkers for CDK4/6 inhibitor resistance in ER+ breast cancer.
Nat Commun
; 13(1): 5258, 2022 09 07.
Article
in English
| MEDLINE | ID: mdl-36071033
18.
Adjuvant Palbociclib for Early Breast Cancer: The PALLAS Trial Results (ABCSG-42/AFT-05/BIG-14-03).
J Clin Oncol
; 40(3): 282-293, 2022 01 20.
Article
in English
| MEDLINE | ID: mdl-34874182
19.
Long-Term Cardiac Safety and Survival Outcomes of Neoadjuvant Pegylated Liposomal Doxorubicin in Elderly Patients or Prone to Cardiotoxicity and Triple Negative Breast Cancer. Final Results of the Multicentre Phase II CAPRICE Study.
Front Oncol
; 11: 645026, 2021.
Article
in English
| MEDLINE | ID: mdl-34307126
20.
Oestrogen receptor activity in hormone-dependent breast cancer during chemotherapy.
EBioMedicine
; 69: 103451, 2021 Jul.
Article
in English
| MEDLINE | ID: mdl-34161883